Aflibercept biosimilar (Amgen)

阿柏西普生物类似药 (Amgen)

Report date: 2024/08/28 10:11:41

Base Information

Drug NameAflibercept biosimilar (Amgen)
Drug Alias NameAflibercept-AYYHPAVBLUABP-938
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaDiabetes ComplicationsVascular Diseases +[9] 
Global Approved IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[7] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/08/23
Country/TerritoryCzechiaCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Technology (Ireland) Unlimited CompanyAmgen Inc
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaDiabetes ComplicationsVascular Diseases +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A